As we look forward to 2024, delivering for patients and investors will happen against a backdrop of the election, burgeoning AI, talent shortages, rising capital costs, challenging foreign exchange impacts, pressures on consumer spending, sticky inflation and ongoing regulatory scrutiny of transactions. These headwinds come on top of blockbuster patent expiries, rising competition across most therapeutic areas and the impact of the Inflation Reduction Act (IRA) of 2022.